Heart failure [Second edition] 9780191655685, 0191655686, 9781306948364, 1306948363

Table of contents :
Cover......Page 1
Series......Page 3
Oxford Specialist Handbooks in Cardiology......Page 4
Copyright......Page 5
Contents......Page 8
Symbols and abbreviations......Page 10
Plates......Page 16
Section I Introduction to heart failure......Page 20
1 Definition of heart failure, basic epidemiology, and pathophysiology......Page 22
Section II Chronic heart failure......Page 36
2 Diagnosis and investigation......Page 38
3 Estimating prognosis......Page 50
4 Non-pharmacological management......Page 62
5 Pharmacological management......Page 70
6 Device therapy: which devices and for whom?......Page 82
7 Coronary revascularization in heart failure......Page 104
8 Other surgical techniques......Page 110
9 Cardiac transplantation......Page 118
10 Mechanical circulatory support......Page 134
Section III Heart failure and co-morbidities......Page 150
11 CHF and adult congenital heart disease......Page 152
12 The patient with CHF and anaemia......Page 166
13 The patient with CHF and angina......Page 172
14 The patient with CHF and arrhythmias......Page 178
15 The patient with CHF and arthritis......Page 190
16 The patient with CHF and cancer......Page 200
17 The patient with CHF and diabetes......Page 212
18 The patient with CHF and obstructive lung disease......Page 218
19 The pregnant patient with HF......Page 222
20 The patient with CHF and preserved LV systolic function (HF-PEF)......Page 234
21 The patient with CHF and renal dysfunction......Page 244
22 The patient with CHF and RV dysfunction......Page 252
23 The patient with CHF and specific heart muscle disease......Page 256
24 The patient with CHF and valvular heart disease......Page 304
Section IV Acute heart failure......Page 322
25 Acute heart failure: from definition to diagnosis......Page 324
26 Acute heart failure: management......Page 336
Section V Procedures......Page 354
27 Central venous cannulation......Page 356
28 Cardiac catheterization......Page 360
29 Endomyocardial biopsy......Page 374
30 IABP insertion......Page 380
31 Cardio-pulmonary exercise testing......Page 386
32 CRT optimization......Page 390
Section VI Detailed pharmacology and evidence base for drugs......Page 394
33 ACE inhibitors......Page 396
34 ß-adrenoreceptor antagonists......Page 404
35 Mineralocorticoid receptor antagonists (MRAs)......Page 414
36 Angiotensin receptor antagonists......Page 422
37 Diuretics and aquaretics......Page 432
38 Rate limiting therapy......Page 442
39 Inotropes and vasopressors......Page 450
40 Vasodilators......Page 464
Section VII Multi-professional heart failure care......Page 474
41 Heart failure services......Page 476
42 Palliative care......Page 486
Index......Page 496

Citation preview

OXFORD MEDICAL PUBLICATIONS

Heart Failure

Oxford Specialist Handbooks published and forthcoming General Oxford Specialist Handbooks A Resuscitation Room Guide Addiction Medicine Day Case Surgery Perioperative Medicine, 2e Pharmaceutical Medicine Postoperative Complications, 2e Renal Transplantation Oxford Specialist Handbooks in Anaesthesia Anaesthesia for Medical and Surgical Emergencies Cardiac Anaesthesia Neuroanaesthesia Obstetric Anaesthesia Ophthalmic Anaesthesia Paediatric Anaesthesia Regional Anaesthesia, Stimulation and Ultrasound Techniques Thoracic Anaesthesia Oxford Specialist Handbooks in Cardiology Adult Congenital Heart Disease Cardiac Catheterization and Coronary Intervention Cardiac Electrophysiology and Catheter Ablation Cardiovascular Computed Tomography Cardiovascular Magnetic Resonance Echocardiography, 2e Fetal Cardiology Heart Failure, 2e Hypertension Inherited Cardiac Disease Nuclear Cardiology Pacemakers and ICDs Pulmonary Hypertension Valvular Heart Disease Oxford Specialist Handbooks in Critical Care Advanced Respiratory Critical Care Cardiothoracic Critical Care Oxford Specialist Handbooks in End of Life Care End of Life Care in Cardiology End of Life Care in Dementia End of Life Care in Nephrology End of Life Care in Respiratory Disease End of Life in the Intensive Care Unit

Oxford Specialist Handbooks in Neurology Epilepsy Parkinson’s Disease and Other Movement Disorders Stroke Medicine Oxford Specialist Handbooks in Oncology Practical Management of Complex Cancer Pain Oxford Specialist Handbooks in Paediatrics Paediatric Dermatology Paediatric Endocrinology and Diabetes Paediatric Gastroenterology, Hepatology, and Nutrition Paediatric Haematology and Oncology Paediatric Intensive Care Paediatric Nephrology, 2e Paediatric Neurology, 2e Paediatric Radiology Paediatric Respiratory Medicine Paediatric Rheumatology Oxford Specialist Handbooks in Pain Medicine Spinal Interventions in Pain Management Oxford Specialist Handbooks in Psychiatry Child and Adolescent Psychiatry Forensic Psychiatry Old Age Psychiatry Oxford Specialist Handbooks in Radiology Interventional Radiology Musculoskeletal Imaging Pulmonary Imaging Thoracic Imaging Oxford Specialist Handbooks in Surgery Cardiothoracic Surgery, 2e Colorectal Surgery Gastric and Oesophageal Surgery Hand Surgery Hepatopancreatobiliary Surgery Neurosurgery Operative Surgery, 2e Oral and Maxillofacial Surgery Otolaryngology and Head and Neck Surgery Paediatric Surgery Plastic and Reconstructive Surgery Surgical Oncology Urological Surgery Vascular Surgery

Oxford Specialist Handbooks in Cardiology

Heart Failure Second Edition

Roy S. Gardner Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital, Clydebank, Glasgow, UK

Theresa A. McDonagh Kings College Hospital, London, UK

Niki L. Walker Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Clydebank, Glasgow, UK

1

3 Great Clarendon Street, Oxford, OX2 6DP, United Kingdom Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries © Oxford University Press 204 The moral rights of the authors have been asserted First Edition published in 2007 Second Edition published in 204 Impression:  All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer Published in the United States of America by Oxford University Press 98 Madison Avenue, New York, NY 006, United States of America British Library Cataloguing in Publication Data Data available Library of Congress Control Number: 204934228 ISBN 978–0–9–96745–2 Printed in China by C&C Offset Printing Co. Ltd Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breast-feeding. Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work.

v

Preface Heart failure is an important and ever expanding sub-speciality of cardiology. Many health care professionals are now developing specialist expertise in heart failure. This is true for cardiologists in training, consultant cardiologists, care of the elderly and general physicians, cardiothoracic surgeons, primary care doctors, pharmacists, and specialist nurses. With advances in medical therapy, the prognosis of the condition has improved dramatically. Where once heart failure was a pre-terminal diagnosis, now for many it is treatable. However, some patients remain symptomatic and at high risk of death despite maximal medical therapy. These patients can now benefit from a range of novel devices and other advanced therapies. Heart failure is an extremely complex condition to both diagnose and manage. This is due in particular to the large burden of co-morbidities involved. This has made multi-professional delivery of heart failure care essential to achieve the best outcomes for patients. This book aims to cover comprehensively all aspects necessary to manage a patient with heart failure. It gives simple, clear advice on the diagnosis, investigation, and treatment options available. The book is set out logically to mirror the patient journey in heart failure. The chapters provide concise and objective information to guide all health care professionals involved in the modern day multi-disciplinary management of the syndrome. In addition it is also designed to be an effective training manual for cardiology juniors and trainees in heart failure specialist nursing programmes. As such, we hope that this book, in the easy to use Oxford Handbook style, will serve as the flagship manual of heart failure management that addresses the needs of all the health care team. Our ultimate desire is that it facilitates the practice of optimal evidencebased management of heart failure to improve outcomes for our patients. RSG TAMcD NLW 204

vii

Contents Symbols and Abbreviations  ix Section I  Introduction to heart failure  Definition of heart failure, basic epidemiology, and pathophysiology Section II  Chronic heart failure 2 Diagnosis and investigation 3 Estimating prognosis 4 Non-pharmacological management 5 Pharmacological management 6 Device therapy: which devices and for whom? 7 Coronary revascularization in heart failure 8 Other surgical techniques 9 Cardiac transplantation 0 Mechanical circulatory support Section III  Heart failure and co-morbidities  CHF and adult congenital heart disease 2 The patient with CHF and anaemia 3 The patient with CHF and angina 4 The patient with CHF and arrhythmias 5 The patient with CHF and arthritis 6 The patient with CHF and cancer 7 The patient with CHF and diabetes 8 The patient with CHF and obstructive lung disease 9 The pregnant patient with HF 20 The patient with CHF and preserved LV systolic function (HF-PEF)

3

9 3 43 5 63 85 9 99 5

33 47 53 59 7 8 93 99 203 25

viii

CONTENTS

2  The patient with CHF and renal dysfunction 22 The patient with CHF and RV dysfunction 23 The patient with CHF and specific heart muscle disease 24 The patient with CHF and valvular heart disease Section IV  Acute heart failure 25 Acute heart failure: from definition to diagnosis 26 Acute heart failure: management Section V  Procedures 27 Central venous cannulation 28 Cardiac catheterization 29 Endomyocardial biopsy 30 IABP insertion 3 Cardio-pulmonary exercise testing 32 CRT optimization Section VI Detailed pharmacology and evidence base for drugs 33 ACE inhibitors 34 β-adrenoreceptor antagonists 35 Mineralocorticoid receptor antagonists (MRAs) 36 Angiotensin receptor antagonists 37 Diuretics and aquaretics 38 Rate limiting therapy 39 Inotropes and vasopressors 40 Vasodilators Section VII  Multi-professional heart failure care 4 Heart failure services 42 Palliative care Index 477

225 233 237 285

305 37

337 34 355 36 367 37

377 385 395 403 43 423 43 445

457 467

CONTENTS

Symbols and abbreviations • warning 2 important 22 don’t dawdle  controversial topic ♂ male ♀ female d decrease i increase l leading to E cross reference M website 6-MWT 6 minute walk test ACC American College of Cardiology ACE angiotensin converting enzyme ACEi angiotensin converting enzyme inhibitor ACTH adrenocorticotrophic hormone ADP adenosine diphosphate AF atrial fibrillation AHA American Heart Association A-HeFT African-American heart failure trial AHF acute heart failure AHI apnoea-hypopnoea index AIRE acute infarction ramipril efficacy study AMI acute myocardial infarction ANP atrial natriuretic peptide AR aortic regurgitation ARB angiotensin II receptor blockers ARVC arrhythmogenic right ventricular cardiomyopathy AS aortic stenosis AT angiotensin II type- ATII angiotensin II ATG antithymocyte globulin ATLAS assessment of treatment with lisinopril and survival trial ATP anti-tachycardia pacing AV atrioventricular AVNRT atrioventricular nodal tachycardia

ix

x

SYMBOLS AND ABBREVIATIONS

AVRT atrioventricular re-entry tachycardia BiPAP bi-level positive pressure support BiVAD biventricular assist device BK bradykinin BMD Becker muscular dystrophy BNP B-type natriuretic peptides BP blood pressure BSA body surface area BTC bridge to candidacy BTD bridge to decision BTR bridge to recovery BTT bridge to transplantation CABG coronary artery bypass graft CAD coronary artery disease CHARM candesartan in heart failure: assessment of reduction in mortality and morbidity trial CHB complete heart block CHD coronary heart disease CHF chronic heart failure CIBIS cardiac insufficiency bisoprolol study CMR cardiac magnetic resonance CNS central nervous system CO cardiac output COCPIT comparative outcome and clinical profiles in transplantation COMET carvedilol or metoprolol European trial COMT catechol-O-methyl transferase CONSENSUS cooperative North Scandinavian enalapril survival study COPERNICUS carvedilol prospective randomized cumulative survival study COX cyclo-oxygenase CPAP continuous positive airways pressure CPET cardio-pulmonary exercise testing CRT cardiac resynchronization therapy CRT-D cardiac resynchronization therapy-defibrillator CRT-P cardiac resynchronization therapy pacemaker CSA central sleep apnoea CTR cardiothoracic ratio CTx cardiac transplantation CVP central venous pressure

SYMBOLS AND ABBREVIATIONS

DAD delayed after depolarization DAVID dual chamber and VVI implantable defibrillator trial DCM dilated cardiomyopathy DD diastolic dysfunction DIC disseminated intravascular coagulation DIG Digitalis Investigation Group DMD Duchenne muscular dystrophy DNA deoxyribonucleic acid EAD early after depolarization ECMO extracorporeal membrane oxygenation ecNOS endothelial cell NOS EDTA ethylene diamine tetraacetic acid EEG electroencephalogram eGFR estimated glomerular filtration rate ELITE evaluation of losartan in the elderly study EMA European Medicines Agency EMF endomyocardial fibrosis EMG electromyography EPHESUS epelerenone post-acute myocardial infrarction heart failure efficacy and survival study ESC European Society of Cardiology FDA Food and Drug Administration FEV forced expiratory volume in  second FVC forced vital capacity Gd gadolinium GFR glomerular filtration rate HCM hypertrophic cardiomyopathy HCP health care professional HDL high-density lipoprotein HES hypereosinophilic syndrome HF heart failure HFSS heart failure survival score HIV human immunodeficiency virus HLA human leukocyte antigen IABP intra-aortic balloon pump ICD implantable cardioverter-defibrillator IL interleukin INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support ISDN isosorbide dinitrate

xi

xii

SYMBOLS AND ABBREVIATIONS

ISHLT IVD IVS LA LBBB LDL LIDO LV LVAD LVEDP LVEF LVH LVNC LVOT LVSD MAGGIC MAO MAOI MAP MCS MDRD MERIT-HF MMF MR MRA MS MTWA MUGA NEP NIPPV NSAID NYHA OSA PA PAC PAFC PAP PCI PCWP

International Society for Heart and Lung Transplantation interventricular delay interventricular septum left atrium left bundle branch block low-density lipoprotein levosimendan infusion versus dobutamine trial left ventricular left ventricular assist device left ventricular end-diastolic pressure left ventricular ejection fraction left ventricular hypertrophy left ventricular non-compaction left ventricular outflow tract left ventricular systolic dysfunction meta-analysis global group in chronic heart failure trial monoamine oxidase monoamine oxidase inhibitor mean arterial pressure mechanical circulatory support modification of diet in renal disease metoprolol CR/XL randomized interventional trial in heart failure mycophenolate mofetil mitral regurgitation mineralocorticoid receptor antagonists mitral stenosis microvolt T-wave alternans multiple-uptake gated acquisition neutral endopeptidase non-invasive positive pressure ventilation non steroidal anti-inflammatory drug New York Heart Association obstructive sleep apnoea pulmonary artery pulmonary artery catheter pulmonary artery flotation catheter pulmonary artery pressure percutaneous coronary intervention pulmonary capillary wedge pressure

SYMBOLS AND ABBREVIATIONS

PDEI PEEP PEF PLVEF PMBV PND PPAR PPCM PPI PR PS PVR RA RhA RAAS RALES RCT REF REMATCH RER REVIVE RNVG RRR RV RVAD SAM SAVE SAVER SBP SCA SCD SDC SENIORS SHFM SLE SNP SNS

phosphodiesterase inhibitors positive end-expiratory pressure preserved ejection fraction preserved LV function percutaneous mitral balloon valvotomy paroxysmal nocturnal dyspnoea peroxisome proliferator-activated receptor peripartum cardiomyopathy proton-pump inhibitor pulmonary regurgitation pulmonary stenosis pulmonary vascular resistance right atrium rhematoid arthritis renin–angiotensin–aldosterone system randomized aldactone evaluation study randomized controlled trials reduced ejection fraction randomized evaluation of mechanical assistance for the treatment of congestive heart failure trial respiratory exchange ratio randomized multi-centre evaluation of intravenous levosimendan efficacy radionuclide ventriculography regular rate and rhythm right ventricular right ventricular assist device systolic anterior motion survival and ventricular enlargement study surgical anterior ventricular endocardial restoration systolic blood pressure senile cardiac amyloidosis sudden cardiac death serum digoxin concentrations study of the effects of nebivolol intervention on outcomes and re-hospitalization in seniors with heart failure trial Seattle heart failure model systemic lupus erythematosis sodium nitroprusside sympathetic nervous system

xiii

xiv

SYMBOLS AND ABBREVIATIONS

SOLVD SPECT SPWMD STICH SUPPORT

studies of left ventricular dysfunction single photon emission computed tomography septal-to-posterior wall motion delay surgical treatment for ischemic heart failure trial study to understand prognoses and preferences for outcomes and risks of treatments SVR systemic vascular resistance TAH total artificial heart TAPSE tricuspid annular plane systolic excursion TDI tissue Doppler imaging TM thrombomodulin TNF-α tumour necrosis factor-α TOE transoesophageal echocardiography TPG transpulmonary gradient TPMT thiopurine methyltransferase TR tricuspid regurgitation TRACE trandolapril cardiac evaluation study TS tricuspic stenosis TTE transthoracic echocardiogram TV tricuspid valve TZD thiazolidinedione UF ultrafiltration VAD ventricular assist device Val-HeFT valsartan heart failure trial Vd volume of distribution VE minute ventilation VO2 respiratory oxygen uptake VMAC vasodilation in the management of acute CHF VTI velocity-time integral VT ventilatory threshold

Fig. 23.4  Sarcoidosis. A central non-caseating granuloma is disrupting the

myocardium with myocyte destruction and early replacement fibrosis. A second granuloma is present at the bottom left. Haematoxylin and eosin ×400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 23.5  Haemochromatosis. Granular intracellular cardiac myocyte deposits of

haemosiderin are stained blue. Perls stain ×400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 23.7  Histopathology of cardiac amyloid, demonstrating apple green

birefringence with polarized light. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 23.8  Amyloidosis—Individual myocytes are ringed by pink-staining extracellullar deposits of amyloid in a case of primary amyloidosis. Sirius red × 400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 23.0  Viral myocarditis. The myocardium contains focal interstitial infiltration by mononuclear cells, with associated cardiac myocyte degeneration. Haematoxylin and eosin x400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 23.  Giant cell myocarditis. The myocardium is being damaged by a marked chronic inflammatory infiltrate that includes prominent multi-nucleated giant cells in the bottom half of the image. Haematoxlin and eosin. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 29.  Normal endocardium and myocardium. The endocardium on the left is

a thin uniform layer with underlying myocardium that comprises cardiac myocytes, which are closely applied to one another with little intervening stroma that includes small blood vessels. Haematoxylin and eosin ×400.Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 29.2  Low-grade cardiac allograft rejection. The myocardium contains small

perivascular aggregates of mononuclear cells (ISHLT Grade a). Haematoxylin and eosin ×400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Fig. 29.3  High-grade cardiac allograft rejection. The myocardium contains perivascular aggregates of mononuclear cells with extension into the interstitium associated with mutiple foci of cardiac myocyte degeneration. Haematoxylin and eosin ×400. Courtesy of Dr Allan McPhaden, Southern General Hospital, Glasgow.

Section 

Introduction to Heart Failure  Definition of heart failure, basic epidemiology, and pathophysiology

3

Chapter 

Definition of heart failure, basic epidemiology, and pathophysiology Definition  4 Epidemiology  5 Aetiology  6 Prognosis  8 Pathophysiology  0

3

4

Chapter   

Definition of heart failure

Definition Physiological—the inability of the heart to pump sufficient oxygenated blood to the metabolizing tissues despite an adequate filling pressure. Working clinical definition—the clinical syndrome consisting of symptoms such as breathlessness, fatigue, and swelling of the ankles caused by cardiac dysfunction. Chronic heart failure (CHF) can be caused by any type of cardiac dysfunction and is most commonly attributable to left-ventricular dysfunction. Only rarely does a patient present with CHF as a result of isolated right-ventricular (RV) dysfunction. RV dysfunction is usually secondary to LV dysfunction and its sequelae. The most common and best-studied cause of CHF is left ventricular systolic dysfunction (LVSD), now known has HF-REF (reduced ejection fraction). CHF also occurs in the presence of preserved systolic function. This is now referred to as HF-PEF (preserved ejection Fraction). Left ventricular systolic dysfunction is relatively easy to diagnose by a range of non-invasive methods. The diagnosis of HF-PEF is more difficult (E Chapter 20). It is often attributed to diastolic dysfunction, although abnormalities of systolic and diastolic function frequently co-exist. To prove diastolic dysfunction, invasive haemodynamics are necessary, but many non-invasive tests can infer its presence.

Classification Heart failure (HF) can present either as a chronic condition or acutely, occurring de novo or as a decompensation of chronic heart failure. Acute HF is covered in E Chapters 25 and 26. Current US guidelines also classify patients into the following stages: Stage A Stage B Stage C Stage D

Those at high risk of developing HF, for example, hypertensives, diabetics. Patients with structural cardiac disease or remodelling who have not yet developed HF, that is, asymptomatic LV dysfunction. Patients with current or prior HF symptoms. Those with end-stage HF.

This system emphasizes the need for prevention of the development of heart failure in the first place by aggressive risk factor control. It also highlights the importance of treating asymptomatic LVSD to prevent its progression to symptomatic LVSD, that is, CHF.

Key references Erikson H et al. Risk factors for heart failure in the general population. Eur Heart J 989; 0: 647–56. Hunt SA et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol 2005; 46: e–82. McDonagh TA et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 997; 350: 829–33. McKee PA et al. The natural history of congestive heart failure. N Engl J Med 97; 285: 44–6. Redfield MM et al. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 2003; 289: 94–202.

Epidemiology

Epidemiology Prevalence • Using clinical criteria, CHF prevalence –2% of population. • ♂ > ♀ • Increased in the elderly (approximately 5%). • European population-based studies of LVSD show: • Prevalence of 2–3%. • Increasing to 7% in the elderly. • Approximately 50% of patients with significant left ventricular systolic dysfunction have no symptoms or signs of heart failure (asymptomatic LVSD). • Prevalence of HF with preserved LVEF 9.7/000 (44% of the total HF prevalence). • Range of prevalence for HF with preserved LVEF varies from 5–50%.

Incidence

Average annual incidence/1000 people

• The Framingham heart study (USA) results show an annual incidence of 0.2–0.3% in those aged 50–59 years, increasing 0-fold in those aged 80–89 (Fig. .). • The UK population data is similar, with an annual incidence of 0.2% in those aged 55–64, rising to .2% in those aged over 85. Median age of presentation is 76 years. • ♂ > ♀, particularly due to LVSD. • HF with preserved LVEF occurs more among: • Elderly individuals • Women • African Americans.

35 30

n = 31 n = 28

Males Females

25 20

n = 17

15 10 5 0

n = 13 n=9 n = 5n = 6 n 2n = 3 n=1 = 45–54

55–64

65–74 75–84 Age (years)

85–94

Fig. .  Incidence of heart failure. Reproduced from McKee PA et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 97; 285: 44–6 with permission from Massacheusets Medical Society.

5

6

Chapter   

Definition of heart failure

Aetiology See Box .. • There is geographical variation. • In Westernized societies, two-thirds are secondary to ischaemic heart disease. • Other important contributors are: • Hypertension • Valve disease • Alcohol. • Rheumatic disease is the most common cause in the developing world. • Chagas disease is an important cause in South America (E Chapter 23). • Hypertension is an important factor in Africans and African Americans. It is proportionately more common in heart failure with preserved LVEF. • There has been a shift in the aetiology over time in long-term population-based studies such as Framingham. • Decreased importance of hypertension. • Increased relevance of ischaemic heart disease (Fig. .2).

Box .  Causes of chronic heart failure • Coronary heart disease. • Hypertension. • Valve disease. • Congenital heart disease. • Infective: for example, viral myocarditis, Chagas, HIV, Lyme disease. • Alcohol. • Toxins: for example, anthracyclines, trastuzimab. • Deficiencies: for example, selenium, beriberi, thiamine. • Haemochromatosis. • Idiopathic. • Familial. • Peripartum. • Tachycardia induced. • Infiltrative states: amyloid, sarcoid, endomyocardial fibrosis, hypereosinophilic syndrome. • High output: for example, A–V fistulae, Paget’s disease.

Change in prevalence per decade (%)

Aetiology

50 40 30 20 10 0 –10 –20 –30 –40 –50

Coronary artery disease

Men Women Diabetes Hypertension

Valvar heart disease

Fig. .2 The changing pattern of aetiology of CHF in the Framingham study with time. Reproduced from McMurray JJ & Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596–602 with permission from BMJ Publishing Group Ltd.

7

8

Chapter   

Definition of heart failure

Prognosis The prognosis in CHF is poor. Population-based studies report significantly lower survival rates than those seen in heart failure treatment trials. • The mortality from CHF at 5 years in the Framingham study (32-year follow up). • 62% in men • 42% in women. • UK data (Fig. .3): • Six-month mortality rate 30% • Over 40% do not survive 8 months from the time of diagnosis. • Mortality rates are in excess of many common solid malignant tumours (breast, prostate, colon, and melanoma). • Population-based studies: survival of HF with preserved LVEF is better. • Hospitalized patients with HF with preserved LVEF: similar mortality rates to those patients with LVSD. • CHF is extremely disabling, with frequent and recurrent hospitalizations. • CHF reduces quality of life to a greater extent than other chronic medical disorders including arthritis and stroke. • CHF is an expensive condition, consuming –2% of total NHS expenditure in the UK. • The mortality of acute heart failure is worse than that of CHF. Over 30% of patients admitted to hospital with heart failure are dead at  year, with around % dying during the admission. Mortality rates vary according to the presentation. They are worst for cardiogenic shock.

Trends in epidemiology CHF is projected to increase in prevalence by 50% in the next 20 years. The prevalence and incidence of CHF are rising due to: • Changing demography of the population, that is, more elderly at risk. • Improved survival of other cardiovascular diseases, for example, MI. • Improved survival rates for CHF.

Prognosis

Cumulative survival (%)

100 90 80 70 60 50 40

Number of patients 220 166 152 0

3

6

126

102

74

49

25

11

9

12

15

18

21

24

Months from identification

Fig. .3  Mortality after a first diagnosis of heart failure. Reproduced from Cowie

MR et al. Survival of patients with a new diagnosis of heart failure. Heart 2000; 83: 505–0 with permission from BMJ Publishing Group Ltd.

Key references Cowie MR et al. Survival of patients with a new diagnosis of heart failure. Heart 2000; 83: 505–0. Ho KK et al. The epidemiology of heart failure. J Am Coll Cardiol 993; 22: A6–3. Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 397–402. The National Heart Failure Audit. M http://www.ucl.ac.uk/nicor

9

10

Chapter   

Definition of heart failure

Pathophysiology Sustained cardiac dysfunction leads to haemodynamic, autonomic, neurohumoral, and immunological abnormalities. These drive the pathway to CHF. Many of the processes are maladaptive, originally designed to protect the organism from exsanguination and hence to maintain blood pressure and vital organ perfusion. The best-described mechanisms are the activation of various neurohormonal systems. In addition, there is intense activation of cytokines and inflammatory markers. These processes combine to cause fluid retention and myocardial cell death leading to a vicious cycle of deteriorating left ventricular performance.

Haemodynamics Decreased cardiac output leads to the following: • i Left ventricular end-diastolic pressure (LVEDP). • i Pulmonary capillary wedge pressure (PCWP). • The development of pulmonary oedema. PCWP is a poor correlate of symptoms because other factors also contribute. Initially, increased filling pressures augment ventricular performance early in the disease process (Frank Starling law), but as the increased filling pressures persist, the myocardium fails and cardiac output drops.

The renin–angiotensin–aldosterone system (RAAS) Decreased cardiac output decreases renal afferent arteriolar blood flow, causing secretion of renin and production of angiotensinogen and angiotensin I. This is converted in the lung by the angiotensin converting enzyme (ACE) to the octapeptide, angiotensin II (ATII) (Fig. .4). ATII is a major effector hormone of this system, causing the following: • Vasoconstriction • Myocyte hypertrophy and fibrosis • Aldosterone release • Activation of noradrenaline and endothelin. Aldosterone causes sodium- and water-retention and hypokalaemia resulting in the following: • Pulmonary and peripheral oedema • Myocardial cell loss via apoptosis • Myocardial fibrosis • Increased afterload.

Pathophysiology

Angiotensinogen Renin Angiotensin I Angiotensin converting enzyme

Chymase Angiotensin II

Sympathetic activation

Arteriolar vasoconstriction Aldosterone

Increased kaluresis

Sodium and water retention

Fig. .4 The renin–angiotensin–aldosterone system.

Key reference Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur J Heart Fail 2000; 2: 229–33.

11

12

Chapter   

Definition of heart failure

The sympathetic nervous system (SNS) Decreased cardiac output activates baroreceptors causing activation of the SNS. The effects of high circulating concentrations of epinephrine and norepinephrine include • i Heart rate. • i Blood pressure. • i Myocardial oxygen demand. • Toxic effects on the myocardium—cell death. • Down-regulation of β receptors in the heart. There is a concomitant decrease in parasympathetic nervous activity.

Other circulating and paracrine effects Other circulating and paracrine effects include increased production of the following: • Endothelin: a potent vasoconstrictor peptide. • Vasopressin: leading to water-retention and vasoconstriction. • Cytokines such as TNF-α, IL-, and IL-6 causing myocyte apoptosis which contribute to the development of cardiac cachexia in advanced HF. • Increased circulating steroid hormones and growth hormone.

Counter-regulatory systems Not all the hormonal systems activated in CHF are deleterious. Various counter-regulatory mechanisms to oppose sodium- and water- retention are also activated, for example, the natriuretic peptide system.

The natriuretic peptide system Myocardial pathology and the increased wall stress caused by a raised LVEDP and LA pressure, lead to LV and LA wall stretch and the secretion of the natriuretic peptide hormones (Fig. .5). These natriuretic peptides cause • Natriuresis. • Vasodilatation. • Offset the activation of the RAAS and SNS. Two types of natriuretic peptide circulate in high concentrations in HF: • Brain natriuretic peptides (Fig. .6) • BNP, the active peptide. • NT-proBNP, the inactive N-terminal cleavage fragment. • Atrial natriuretic peptide (ANP and NT-ANP). Adrenomedullin, another natriuretic hormone is also produced and circulates in higher concentration. When heart failure progresses the more powerful negative effects of the RAAS and SNS outweigh these beneficial processes.

Pathophysiology

Fig. .5 The natriuretic peptides. From Heart Failure in Clinical Practice (2nd edition)

edited by McMurray J & Cleland J. Martin Dunitz Ltd, London, 2000, (Figure 5.) with permission from Taylor and Francis.

ProANP 1

98

99

126 ANP

N-terminal proANP(1–98) ProBNP 76

1 N-terminal proBNP(1–76)

77

108 BNP

Fig. .6  Cleavage of pro-hormones of BNP and ANP into active peptides and inactive N-terminal fragments.

Key reference Rademaker MT & Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) 2005; 08: 23–36.

13

14

Chapter   

Definition of heart failure

Peripheral changes Abnormalities of skeletal muscle occur in CHF, including: • Wasting. • Impaired perfusion. • Increased fatigability. • Abnormal histology and metabolism. These correlate with symptoms of fatigue, exercise-intolerance, and poor prognosis. These changes may be secondary to • Physical inactivity, anorexia, and poor intestinal absorption. • Insulin resistance, TNF-α, and norepinephrine.

Arrhythmias The CHF syndrome is associated with an increased propensity for both atrial and ventricular arrhythmias. In particular, the development of atrial fibrillation (AF) can contribute to the further deterioration of LV function. There are multiple mechanisms for arrhythmias in CHF, including structural changes, ischaemia, and neurohormonal activation (E Chapter 4). Additional factors such hypo- and hyperkalaemia, hypo- and hypermagnesaemia, drug interactions, and toxicity may precipitate arrhythmias.

Co-morbidities CHF is frequently associated with co-morbidities that can lead to progression and deterioration. These can occur due to the HF syndrome, the treatment, or due to other diseases, for example, diabetes. The commonest co-morbidities are • Renal dysfunction: eGFR 90%. • B-type natriuretic peptide (BNP or NT-proBNP): a value within the normal range has an extremely high negative predictive value (>98%) for the exclusion of HF (Fig. 2.4). • Increased values indicate either a cardiac functional/structural abnormality or renal dysfunction. • BNP/NT-proBNP concentrations: —  i with age in normal individuals. —  higher in ♂ than ♀. —  age–sex corrected normal values may aid diagnosis. • Increased BNP/NT-proBNP concentrations need further investigation and cardiac assessment. • CXR: A normal chest x-ray does not exclude a diagnosis of heart failure as the cardiothoracic ratio (CTR) is normal in 50% of cases. • Cardiomegaly (CTR >0.50) may be suggestive of a cardiac abnormality, particularly with evidence of pulmonary congestion. • Helps to identify and exclude other causes of breathlessness.

Diagnosis of cardiac dysfunction LV function is usually assessed non-invasively by echocardiography. The types of cardiac dysfunction (i.e. myocardial, valvular, or pericardial) should be identified. Other modalities can be used, for example, nuclear techniques, cardiac MR, or invasive contrast ventriculography at cardiac catheterization. For myocardial dysfunction the detection of systolic dysfunction is a crucial preliminary step. The most common way of expressing myocardial performance is by the calculating the LVEF. LVEF (% ) =

LVdiastolic volume − LVsystolic volume x 100. LVdiastolic volume

23

24

Chapter 2  

Diagnosis and investigation

Fig. 2. The ESC guidelines for the diagnosis of HF and LV dysfunction. *In

the acute setting, MR-proANP may also be used (cut-off point 20 pmol/L, i.e. 75 years), atrial arrhythmias, left ventricular hypertrophy, chronic obstructive pulmonary disease, and chronic kidney disease. cTreatment may reduce natriuretic peptide concentration, and natriuretic peptide concentrations may not be markedly elevated in patients with HF-PEF. d See E Diagnosis of underlying aetiology, p. 27. Reproduced from McMurray J, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 202. Eur Heart J 202; 33: 787; with permission from Oxford University Press.

Key references Hunt SA et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 200 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol 2005; 46: e–82. McMurray JJ et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 202; 33: 787. NICE Guideline for Heart Failure: M http://www.nice.org.uk

Diagnosis of HF

Echocardiography LV function and dimensions are usually determined by echocardiography. An accurate LVEF can be obtained by the biplane Simpson’s rule method* (Fig. 2.2). Simpler and more common methods include: • Regional wall motion scores. • Global subjective assessment (eye ball technique). • A–V plane displacement. • M-mode fractional shortening only measures basal function. In systolic dysfunction, the LV is frequently dilated and valve pathology is often identified. Identifying abnormalities of diastolic function is much more complicated by echocardiography. Simple methods such as the E/A ratios on mitral pulsed-wave Doppler are confounded by age and loading conditions. Newer methods including pulmonary venous flow modalities and most recently tissue Doppler imaging provide more accurate results, which compare well with invasive haemodynamic parameters**. The findings of left ventricular hypertrophy (LVH) and increased left atrial volume (LA vol) are becoming increasingly important in the diagnosis of HF-PEF (E Chapter 20).

Cardiac magnetic resonance (CMR) CMR (Fig. 2.3) provides accurate information on LV size, volumes, and LVEF. It is the most reliable non-invasive test for LVH and calculations of LV mass. 2 CMR can be used in patients with coronary artery stents and metallic valves but not with current pacemakers/ICDs.

Nuclear cardiology Calculation of the LVEF (Fig. 2.3) by multiple-uptake gated acquisition scans with Technetium 99 (MUGA) or radionuclide ventriculography (RNVG) provides a more accurate and reproducible result than echocardiography.

Angiographic LV function Contrast, biplane LV (Fig. 2.3) angiography provides an accurate measure of LV systolic function. The gold standard of measurement of diastolic dysfunction is the assessment of pressure volume loops during invasive haemodynamic studies.

Normal range of LVEF LVEF is a normally distributed variable. Cut-off points for LVSD vary by the technique used and by centre, for example, Echo LVSD LVEF 5) in those with in those with high LV filling pressure, low (70 years of age with HF and randomized them to nebivolol or placebo. One-third of them had a previous hospitalization for HF-PEF, LVEF >35%. The reduction in the composite endpoint of death or CV hospitalization seemed to be reduced to a similar extent in those with preserved LVEF as in those with systolic dysfunction. The target dose of nebivolol was 0mg. ACEi should be useful as they increase diastolic distensibility and relaxation, in addition, they are antihypertensive agents capable of causing regression of LVH and fibrosis. The PEP-CHF trial randomized 850 HF patients who were at least 70 years of age and had an LVEF of ≥45% and echocardiographic features suggesting possible diastolic dysfunction to receive perindopril at 4mg/day or placebo. Perindopril’s effect on the primary endpoint after  year fell short of significance overall (p = 0.055). However, there were significant reductions in several subgroups, including patients aged 75 or younger (p = 0.035), or those with a prior MI (p = 0.004). Significant improvements were observed compared with the placebo group in some secondary endpoints, including the proportion of patients in NYHA functional class  (p 45

37

CHARM

Candesartan

32

 850

≥45

26

PEP-CHF

Perindopril

4

3023

>40

36.6

I-PRESERVE

Irbesartan

300

428

≥45

49.5

*Digoxin dose was titrated by an algorithm (range 0.25–0.5mg), median dose at randomization was 0.25mg. Source: Data from The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 997; 336: 525–33.

Table 20.3  Results of treatment in RCTs in patients with HF and PLVEF Study

HR (95% CI) for ' end point, p value

HF hospitalization

DIG study

0.82 (0.63–.07, p = 0.36

0.79 (0.59–.04), p = 0.094

PEP CHF

0.92 (0.70–.2), p = 0.545

0.63 (0.4–0.97), p = 0.033

CHARM

0.86 (0.74–.00), p = 0.05

0.84 (0.7–.00), p = 0.047

I-PRESERVE

0.95 (0.86–.05), p = 0.35

0.95 (0.8–.), p = 0.50

Source: Data from The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 997; 336: 525–33. Primary endpoints (Table 20.3) Dig Ancillary Study: HF mortality or HF hospitalization. PEP-CHF: All cause mortality or unplanned HF hospitalization. CHARM; CV mortality or HF hospitalization. I-PRESERVE: death or cardiovascular hospitalization.

Key references Ahmed A et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006; 4: 397–403. Cleland JG et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45. Massie BM et  al Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. NEJM 2008: 359: 2456–67. Yusuf S et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 778–8.

Chapter 2

The patient with CHF and renal dysfunction Introduction  226 Definition  226 Prevalence  226 Aetiology  226 Investigation  228 Prognosis  229 Management  229 What to do with heart failure therapy  230

225

226

Chapter 2  

CHF and renal dysfunction

Introduction Chronic heart failure can be seen, as not only a cardiac disorder, but also a cardio-renal and neurohumoral syndrome. Renal impairment is therefore common in patients with chronic heart failure. The proportion of those who have renal dysfunction increases with deteriorating NYHA functional class. A reduced glomerular filtration rate (GFR) is also associated with increased symptoms, more frequent hospitalizations, and an increased mortality rate.

Definition Serum creatinine concentration, which is often quoted as a barometer of renal impairment, is a poor indicator of renal function. Serum creatinine is determined by a number of factors other than GFR, such as gender, age, muscle mass, and ethnicity. Therefore, estimation of the GFR is preferred for the accurate assessment of renal function. A ‘normal’ estimated GFR is regarded as being 20±25mL/min/.73m2 (95th centiles). Males have a slightly higher GFR than females. With age, GFR tends to fall (to approximately 00mL/min/.73m2 at age 70), although serum creatinine does not rise substantially in healthy individuals. Therefore values >90mL/min/.73m2 can be regarded as normal for most patients. A GFR below 60mL/min/.73m2 is associated with complications of renal disease.

Prevalence The prevalence of renal dysfunction in CHF depends greatly on the population studied, and the definition used. In the CHARM trials, the overall prevalence of a eGFR